Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Status:
Withdrawn
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether treatment with cenersen in combination with 4
cycles of high and low-dose chemotherapy (idarubicin and cytarabine) improves the complete
response rate in acute myelogenous leukemia (AML) patients ≥ 55 years of age who did not show
a response (CR, CRi, or PR) to a single aggressive frontline induction course.